Viral Vector Cell Transduction Time Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The conventional method of transferring recombinant nucleic acids into immune effector cells for tumor immunotherapy is time-consuming, requiring over a day for viral vector infection and transduction, leading to increased costs and risks of cell mutation, and delaying tumor treatment.
Innovation Solution
A method involving co-incubation of cells with a stimulator and viral vector particles carrying recombinant nucleic acid for a reduced incubation time of 1-72 hours, significantly shortening the preparation time for receptor-modified cells without compromising efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional viral vector transduction method is used, then transduction efficiency is achieved, but preparation time is extended to more than one day
Solution Approach 1:
The patent changes the temporal parameter of the transduction process by reducing the incubation time from conventional durations (more than one day) to a shortened period (1-2 days). This is achieved by optimizing the co-incubation conditions of cells, stimulators, and viral vectors, allowing efficient transduction to occur in compressed timeframes without sacrificing transduction efficiency
Solution Approach 2:
The patent applies preliminary action by pre-activating cells with stimulators before adding viral vectors, and by optimizing the timing and conditions of each step in the transduction sequence. This preparatory optimization enables the overall process to be completed faster while maintaining effectiveness
2Manufacturing precision
If conventional transduction process is used, then cells are adequately transduced, but cell mutation risk increases due to extended preparation time
Solution Approach 1:
By changing the time parameter from conventional extended durations to a shortened 1-2 day protocol, the patent reduces the window of opportunity for cell mutations to occur while still achieving complete transduction. The optimized conditions ensure that essential transduction events occur within this compressed timeframe
Solution Approach 2:
The patent rushes through the transduction process by eliminating unnecessary delays and optimizing each step to occur as quickly as possible. The co-incubation and transduction steps are streamlined to complete in 1-2 days rather than extending beyond one day, thereby reducing exposure time that could lead to mutations
3Manufacturing precision
If conventional transduction method is used, then recombinant nucleic acid is transferred into cells, but treatment timing is delayed affecting clinical efficacy
Solution Approach 1:
The patent changes the time parameter of the entire workflow from conventional extended timelines to an accelerated 1-2 day protocol. By optimizing the transduction conditions and reducing incubation periods, the patent enables rapid production of transduced cells that can be quickly administered to patients, improving treatment timing without compromising nucleic acid transfer efficiency
Solution Approach 2:
The patent maintains continuous useful action by optimizing the sequence and timing of steps so that transduction, cell preparation, and readiness for administration occur in a continuous streamlined process rather than with unnecessary interruptions or delays. This enables the full process to be completed within 1-2 days
Data Source
AI summary
Provided is a method for transducing cells with a viral vector, and further provided are cells obtained through recombination or heterologous gene transduction and compositions thereof, and a method for using same in adoptive immunotherapy. Under the premise of not affecting the expression of recombinant nucleic acid, the method shortens the activation and transduction time during the preparation process of genetically engineered cells.